0
Cara Therapeutics Inc
- 51-200 Employees
- Based in Stamford, Connecticut
Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment to improve the lives of patients suffering from pruritus. The company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA and EMA approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The company is developing an…More
Cara Therapeutics Inc
Most Recent Responsibility Report
Report Locked. Cara Therapeutics Inc has reached its limit for free report views.
Cara Therapeutics Inc does not currently have any hardcopy reports on ResponsibilityReports.com. Click the button below to request a report when hardcopies become available.
Please fill out the form below and click "Place Order" to complete your order.
Archived Responsibility Reports
-
2022 Environmental, Social and Governance Report View Environmental, Social and Governance Report Download
Our service enables potential investors to review the most recent and archived Cara Therapeutics Inc Sustainability Report, Cara Therapeutics Inc Corporate Social Responsibility Report, Cara Therapeutics Inc CSR Report, Cara Therapeutics Inc Corporate Responsibility, Cara Therapeutics Inc CR Report, Cara Therapeutics Inc Citizenship Report, Cara Therapeutics Inc ESG Report, and Cara Therapeutics Inc Environmental Report online.